Ridley David B, Bei Xiaoshu, Liebman Eli B
David B. Ridley (
Xiaoshu Bei is a doctoral candidate at the Fuqua School of Business, Duke University.
Health Aff (Millwood). 2016 Feb;35(2):235-41. doi: 10.1377/hlthaff.2015.0420.
In 2004 an Institute of Medicine report warned of vaccine shortages, raising concerns about disease outbreaks. More than a decade later, we looked for progress in reducing vaccine shortages. We analyzed data on vaccine sales and shortages reported by practitioners and patients to the Food and Drug Administration and the American Society of Health-System Pharmacists in the period 2004-13. We found that the number of annual vaccine shortages peaked in 2007, when there were shortages of seven vaccines; there were only two shortages in 2013. There were no shortages of vaccines with a mean price per dose greater than $75 during the study period. Furthermore, we found that a 10 percent increase in price was associated with a nearly 1 percent decrease in the probability of a shortage. Government payers should carefully consider the benefits of averting shortages when evaluating prices for vaccines, including older vaccines whose prices have been subject to congressional price caps.
2004年,医学研究所的一份报告对疫苗短缺发出警告,引发了对疾病爆发的担忧。十多年后,我们探寻了在减少疫苗短缺方面取得的进展。我们分析了2004年至2013年期间从业者和患者向美国食品药品监督管理局以及美国卫生系统药师协会报告的疫苗销售和短缺数据。我们发现,年度疫苗短缺数量在2007年达到峰值,当时有七种疫苗短缺;2013年仅有两种短缺情况。在研究期间,每剂平均价格超过75美元的疫苗没有出现短缺。此外,我们发现价格上涨10%会使短缺概率降低近1%。政府支付方在评估疫苗价格时,应仔细考虑避免短缺带来的益处,包括那些价格受到国会价格上限限制的老疫苗。